Identification of a Novel Homozygous Nonsense Mutation Confirms the Implication of GNAT1 in Rod-Cone Dystrophy

PLoS One. 2016 Dec 15;11(12):e0168271. doi: 10.1371/journal.pone.0168271. eCollection 2016.

Abstract

GNAT1, encoding the transducin subunit Gα, is an important element of the phototransduction cascade. Mutations in this gene have been associated with autosomal dominant and autosomal recessive congenital stationary night blindness. Recently, a homozygous truncating GNAT1 mutation was identified in a patient with late-onset rod-cone dystrophy. After exclusion of mutations in genes underlying progressive inherited retinal disorders, by targeted next generation sequencing, a 32 year-old male sporadic case with severe rod-cone dystrophy and his unaffected parents were investigated by whole exome sequencing. This led to the identification of a homozygous nonsense variant, c.963C>A p.(Cys321*) in GNAT1, which was confirmed by Sanger sequencing. The mother was heterozygous for this variant whereas the variant was absent in the father. c.963C>A p.(Cys321*) is predicted to produce a shorter protein that lacks critical sites for the phototransduction cascade. Our work confirms that the phenotype and the mode of inheritance associated with GNAT1 variants can vary from autosomal dominant, autosomal recessive congenital stationary night blindness to autosomal recessive rod-cone dystrophy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Codon, Nonsense*
  • Cone-Rod Dystrophies / genetics*
  • DNA Mutational Analysis
  • Heterotrimeric GTP-Binding Proteins / genetics*
  • High-Throughput Nucleotide Sequencing
  • Homozygote
  • Humans
  • Male
  • Retinitis Pigmentosa / genetics
  • Transducin

Substances

  • Codon, Nonsense
  • GNAT1 protein, human
  • Heterotrimeric GTP-Binding Proteins
  • Transducin

Grants and funding

The study was supported by Fondation Voir et Entendre (http://www.fondave.org/) (CZ), Prix Dalloz for “La recherche en ophtalmologie” (CZ), LABEX LIFESENSES [reference ANR-10-LABX-65] supported by French state funds managed by the Agence Nationale de la Recherche within the Investissements d'Avenir program [ANR-11-IDEX-0004-0] (http://www.agence-nationale-recherche.fr/investissements-d-avenir/), Foundation Fighting Blindness center grant [C-CMM-0907-0428-INSERM04] (http://www.blindness.org/), Prix de la Fondation de l’Œil (IA), and doctoral funding from the Ministère de l’Enseignement Supérieur et de la Recherche (MESR) (http://www.enseignementsup-recherche.gouv.fr/) (CM). IntegraGen SA (Genopole, Campus, Evry, Paris, France) provided support in the form of salaries for authors SB, ML and JPS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.